OBJECTIVES: to describe the use of stimulants in a group of Mexican children with ADHD in order to know some pharmacoepidemiological data METHODS: An observational and descriptive study in pediatrics patients based on a survey in a one year period (June 2009 to June 2010) was done. Survey was answered by children parents who signed an informed consent. Patients with diagnosis of ADHD and/or received stimulant treatment with and without co-morbidity were considering. RESULTS: Of 124 surveys, 85 were selected according to inclusion criteria. 61.2% of patients received pharmacologic treatment; the drug most use among them was the stimulant methylphenidate (94%). The mean age of stimulant users was 7.94 years (4-13 years), 81.2% were male, 76.5% were in a primary school and 94% had a non-pharmacologic treatment. The average daily dose was 13.95mg. Immediate release was the most prescribed form in three different commercial presentations, and 8% received the long term release. Children with seven years old were who received more methylphenidate prescription. The age and having a comorbidity increased the probability (p<0.005) for receiving methylphenidate treatment. The most frequent side effect reported was loss of appetite. CONCLUSIONS: Methylphenidate in an immediate action form was the most prescribed stimulant drug in seven years old children with ADHD in the population studied. High percentage of children received methylphenidate treatment.